首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献，搜索用时 203 毫秒
1.
牛病毒性腹泻弱毒活疫苗免疫持续期的研究   总被引：1，自引：1，他引：0  
为检测牛病毒性腹泻病毒(BVDV)弱毒活疫苗在免疫牛体内抗体产生及其消长规律,评价弱毒疫苗的保护效力,并确定免疫持续期,本试验对免疫试验牛每头颈部肌肉接种BVDV SM株弱毒疫苗104.5TCID50/头,监测血清抗体效价,进行免疫持续期的确定。在疫苗免疫后的6、9和12个月分别抽取5头免疫组和5头对照组牛采用BVDV-JL强毒株进行攻毒试验,每头牛攻毒剂量为6×107.0 TCID50/mL。结果显示疫苗免疫后12个月时血清中和抗体效价仍维持在1∶1048以上,攻毒结果显示3个时间点强毒攻击后,免疫组所有动物白细胞数量都没有下降也没有分离到病毒,而对照组动物白细胞数下降均超过30%,6和9个月动物均分离到病毒,而12个月对照组动物由于年龄大,没有分离到病毒,因此暂定此疫苗的免疫持续期为9个月。  相似文献   

2.
为检测牛传染性鼻气管炎病毒(IBRV)抗体在免疫牛体内的产生及其消长规律,评价IBRV LNM株致弱疫苗的保护效力,并确定免疫持续期,本实验对免疫试验组牛每头颈部肌肉接种制备的IBRV LNM株致弱疫苗104.5 TCID50/mL,监测血清抗体效价,进行免疫期的确定。在疫苗免疫后的6个月、9个月和12个月分别抽取3头免疫组和两头对照组牛采用IBRV-LN01/08强毒株进行攻毒试验,每头牛的攻毒剂量为107.0 TCID50/mL。结果显示疫苗免疫后12个月时,中和抗体效价仍维持在1∶11以上。攻毒结果显示3个时间点强毒攻击后,疫苗对免疫牛均具有良好的保护力。研究表明IBRV弱毒疫苗可有效地保护免疫牛抵抗IBRV强毒株的攻毒,其免疫持续期最少为12个月。  相似文献   

3.
本试验使用3~6月龄健康易感牛9头(牛传染性鼻气管炎病毒(IBRV)和牛病毒性腹泻病毒(BVDV)抗原、抗体均阴性),共分3组,每组3头犊牛。第1组首免肌肉注射IBRV-LNM弱毒疫苗株种毒,接种1周后,每头牛接种BVDV-SM弱毒疫苗株;第2组只接种BVDV-SM弱毒疫苗株种毒,接种时间同第1组;第3组为对照组,接种MDBK细胞培养液。接种BVDV-SM疫苗毒后每周采血至疫苗毒接种后28 d,测定接种后BVDV抗体效价,并采用BVDV-JL检验用强毒进行攻毒试验。结果表明,第1组与第2组试验动物血清中牛病毒性腹泻病毒抗体水平无明显差异,能够抵抗BVDV-JL强毒攻击达到免疫保护的效果,说明牛传染性鼻气管炎病毒IBRV-LNM弱毒疫苗株接种后在牛体内对牛病毒性腹泻病毒BVDV-SM疫苗毒不产生免疫干扰作用。  相似文献   

4.
利用微量血清中和试验和攻毒试验、牛传染性鼻气管炎弱毒活疫苗检测免疫后牛血清中牛传染性鼻气管炎病毒的抗体效价及其与保护效力的平衡关系。40头牛其中弱毒活疫苗免疫牛30头,对照牛（抗体阴性牛）10头,采用不同剂量免疫（10^3.5～10^6.5TCID50／mL）,按抗体效价高低将实验动物分,并用IBRV LN01／08强毒株攻击,将攻毒保护结果与攻毒时抗体效价结果平行比较分析,结果显示,当IBRV抗体效价高于1：6时,疫苗免疫可以对牛产生良好的保护效力,保护率在80％以上,低于1：6但高于1：3时,免疫苗抗体阳性牛攻毒后保护率近78％。试验结果显示牛传染性鼻气管炎活疫苗的抗体水平于保护效力之间存在一定的平行关系。  相似文献   

5.
张淑琴  郭利  武华 《中国奶牛》2012,(23):37-38
本研究分析了牛病毒性腹泻弱毒疫苗研制过程中的部分试验数据,对其免疫抗体水平与攻毒保护的关系进行了探究。结果显示,血清中BVDV的抗体效价高于1∶128时,攻强毒的动物得到了完全保护。试验结果表明,牛病毒性腹泻弱毒疫苗的免疫抗体水平与保护效力之间存在一定的平行关系。  相似文献   

6.
用实验室配制的口蹄疫油佐剂和leo佐剂A型弱毒灭活疫苗各免疫6月龄健康敏感牛（乳鼠中和抗体滴度小于1：4）5头，免疫后每月采血一次，分离血清；采用固定病毒稀释血清的方法，通过乳鼠中和试验检测免疫牛血清中的口蹄疫A型中和抗体的产生与消长情况，用karber法计算中和效价，绘制动态曲线图。结果显示，口蹄疫弱毒灭活疫苗免疫牛，可以产生高滴度的血清中和抗体，免疫牛血清中和抗体效价均在免疫后1个月左右达到高峰。油佐剂疫苗免疫的牛，血清中和抗体效价比较高，但下降比较迅速；leo佐剂疫苗免疫的牛，血清中和抗体效价比较低，但下降比较平缓。  相似文献   

7.
本研究目的在于用O型口蹄疫金标试纸条研究免疫动物抗体效价与攻毒保护之间的对应关系以及免疫牛抗体消长规律.用金标试纸条检测了口蹄疫O型疫苗质量标准规定的牛、羊和猪免疫和攻毒血清抗体效价及不同免疫程序的牛血清效价.结果显示,当牛、猪和羊免疫血清稀释≥1∶8时,试纸条是阳性结果,表示有99％的被免疫动物属于抗体水平保护范围;被检测血清稀释≤1∶2时,是阴性结果,表示被免疫动物抗体水平属于不保护范围;血清稀释1∶2～1∶8时,是阳性结果,表示有50％的被免疫动物属于抗体水平保护范围.牛在首次免疫8周后加强免疫可以获得良好的保护率和保护时间.通过本试验确定了金标试纸条检测免疫动物抗体效价与攻毒保护之间的关系及牛加强免疫最佳的时间.  相似文献   

8.
猪瘟病毒低毒力毒株FJFQ株的分离鉴定   总被引：3，自引：0，他引：3  
从福建某猪场分离到 1 株病毒,其在PK 15细胞上的毒价为 106.5 TCID50/mL,该病毒能被猪瘟病毒高免血清所中和(效价为1∶8)。通过 RT -PCR 扩增出猪瘟病毒约250 bp的E2蛋白主要抗原编码区序列,其与几株已发表毒株序列的核苷酸及氨基酸同源性分别为79.9%~87.9%,77.7%~86.6%,与Alfort 株同属于基因二群。经本动物传3代均不表现明显的临床症状。用猪瘟兔化弱毒疫苗免疫后以此分离毒作强攻进行免疫保护相关实验,结果免疫组猪在攻毒前及攻毒后扁桃体 HCFA检测均为阴性,对照组猪扁桃体HCFA于攻毒后1周开始出现阳性结果,且一直持续到试验结束。用分离株免疫本动物后再攻石门毒, 2 头试验猪中 1 头死亡,1头出现临床症状。初步说明,所分离的病毒为猪瘟病毒(命名为CSFV- FJFQ株),可能是一株低毒力毒株,且其免疫原性不好。  相似文献   

9.
为了开发针对牛病毒性腹泻病毒(BVDV)流行毒株的新型疫苗,试验采用以BVDV-1b亚型毒株(SC株)和白油为疫苗株和佐剂,制备了BVD油乳剂灭活疫苗,并通过抗体消长规律和免疫攻毒保护试验对灭活疫苗的免疫效果进行了研究。结果表明:该疫苗具有良好的安全性;用该疫苗给牛免疫1.0 mL和2.0 mL后的第21天中和抗体效价达到峰值,在免疫4.0 mL后的第30天中和抗体效价达到峰值,其中4.0 mL的免疫剂量在免疫后第180天中和抗体效价仍维持在6.0 lb以上;该疫苗在免疫2.0 mL后的21 d内均能够有效保护BVDV-1b强毒株的攻击,保护率达100%。说明BVDV油乳剂灭活疫苗具有良好的安全性和免疫原性,为我国研发具有自主知识产权的BVDV疫苗奠定了基础。  相似文献   

10.
为研制牛传染性鼻气管炎病毒(IBRV)灭活疫苗,本研究以国内分离鉴定的IBRV LN01/08株为种毒,优化病毒增殖条件,获得病毒滴度达108.0TCID50/mL,将其灭活制备疫苗.为比较不同免疫佐剂的效果,分别以矿物质白油和Montanide ISA206佐剂配制灭活疫苗,进行牛体免疫试验.临床观察和血清中和抗体检测结果表明,Montanide ISA206佐剂乳化的疫苗在降低副反应和增强免疫效果方面优于矿物质白油佐剂.应用Montanide ISA206佐剂制备3批灭活疫苗,并对其安全性和免疫保护效果进行测定.结果表明该疫苗安全可靠,对强毒攻击可产生较好的抵抗力,攻毒保护率达80%.疫苗在2℃～8℃保存12个月后仍能保持良好的免疫效果.  相似文献   

11.
OBJECTIVE: To compare antibody responses, feedlot morbidity and mortality rates, feedlot performance, and carcass value for calves vaccinated with 1 of 2 vaccination strategies and for unvaccinated control calves. DESIGN: Randomized controlled clinical trial. ANIMALS: 451 beef steers and heifers. PROCEDURES: Calves were vaccinated with a modified-live infectious bovine rhinotracheitis virus (IBRV), bovine viral diarrhea virus types 1 (BVDV1) and 2 (BVDV2), parainfluenza type 3 virus, and bovine respiratory syncytial virus vaccine and Mannheimia haemolytica and Pasteurella multocida bacterin-toxoid at approximately 67 and 190 days of age (group 1; n = 151) or at approximately 167 and 190 days of age (group 2; 150) or were not vaccinated (control; 150). Serum antibody titers were measured at approximately 2, 67, 167, 190, and 232 days of age. Morbidity and mortality rates, feedlot performance, and carcass value were recorded for 361 calves shipped to feedlots. RESULTS: Percentages of calves seroconverting to IBRV, BVDV1, and BVDV2 were significantly higher for groups 1 and 2 than for the control group. Mean treatment costs were significantly lower for vaccinated than for control calves, and mean mortality rate was significantly higher for control calves than for group 1 calves. Feedlot performance and carcass value did not vary significantly among groups. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that vaccination of beef calves with a 5-antigen modified-live virus vaccine at 67 and 190 days of age was as effective in terms of immunologic responses as was vaccination at 167 and 190 days of age.  相似文献   

12.
Bovine viral diarrhea virus (BVDV) has been segregated into two genotypes, type 1 and type 2. To determine the efficacy of the commercially available bovine viral diarrhea type 1 vaccine used in Japan against BVDV type 2, calves were infected with BVDV type 2 strain 890 4 weeks after administration of the vaccine. The vaccinated calves did not develop any clinical signs and hematological changes such as observed in unvaccinated calves after the challenge. Furthermore, the challenge virus was not recovered from the vaccinated calves throughout the duration of the experiment, whereas it was recovered from all unvaccinated calves. The bovine viral diarrhea vaccine used in Japan is efficacious against infection with BVDV type 2 strain 890.  相似文献   

13.
Serum antibody analyses for bovine herpesvirus type 1 (BHV-1), bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), bovine coronavirus (BCV), and bovine rotavirus (BRV) were performed on 527 randomly selected cows, before calving, and on 407 three-week-old calves. In cows and calves, BCV and BRV were the most seroprevalent viruses (80% to 100% according to virus and vaccination status). Bovine respiratory syncytial virus was the least seroprevalent in the cows, independent of the vaccination status. In nonvaccinated cows the seroprevalence to BRSV was 36.7%, and 53.5% in cows vaccinated less than two weeks prior to collecting blood, and 67.6% in cows vaccinated two weeks or more prior to blood collection. In their calves, BHV-1 was the least seroprevalent, independent of the vaccination status. The serological status and antibody titers in calves were generally associated with those of the dam. The occurrence of respiratory diseases in the calves was associated with cow and calf serological profiles (BHV-1, BRSV and BCV in the nonvaccinated group, BHV-1, BVDV and BCV in the vaccinated group). The occurrence of diarrhea was not associated with cow and calf serological profiles but was negatively associated with high level calf serum IgG in the nonvaccinated group (odds ratio = 0.73). Bovine coronavirus and BRV were shed by 1.4% and 4.9% of calves in the nonvaccinated group, and by 0% and 9.9% of calves in the vaccinated group, respectively. Bovine rotavirus shedding was associated with fecal diarrheic consistency at the moment of fecal sampling but not with previous occurrence of diarrhea.  相似文献   

14.
A field trial was conducted to compare the serological responses in calves to eight commercial vaccines against infectious bovine rhinotracheitis virus (IBRV), parainfluenza-3 virus (PI3V), bovine respiratory syncytial virus (BRSV), and/or bovine viral diarrhea virus (BVDV). Calves given IBRV, P13V, BRSV, and BVDV vaccines had significantly higher antibodies to these viruses than unvaccinated controls; however, serological responses to killed BVDV vaccines were low. Calves with preexisting antibodies to IBRV, PI3V, BRSV, and the Singer strain of BVDV had lower seroconversion rates following vaccination than calves that were seronegative initially.

Serological responses in calves to IBRV, PI3V, BRSV, and BVDV differed among various commercial vaccines. Antibody titers to IBRV were higher in calves vaccinated with modified-live IBRV vaccines than in those vaccinated with killed IBRV vaccines. Following double vaccination with modified-live IBRV and PI3V vaccines, seroconversion rates and antibody titers to IBRV and PI3V were higher in calves vaccinated intramuscularly than in those vaccinated intranasally. Calves given Cattlemaster 4 had significantly higher titers to BRSV and PI3V, and lower titers to BVDV, than calves given Cattlemaster 3, suggesting that the addition of BRSV to Cattlemaster 4 caused some interaction among antigens.

  相似文献   

15.
  相似文献   

16.
Field trials were carried out in calves using a live bovine respiratory syncytial (BRS) virus vaccine prepared from the attenuated BRS virus, strain rs-52. Two hundred seventy-five and 353 calves were vaccinated intranasally and intramuscularly, respectively. No undesirable postvaccinal reactions were observed in the vaccinated calves. Of the serum neutralizing (SN) antibody negative calves 89.7% (26/29) and 92.8% (90/97) developed SN antibody 1 month after intranasal and intramuscular vaccination, respectively. Most of the calves having SN antibody titers of 1:1 or 1:2 at the time of vaccination showed a significant increase in SN antibody titer. About 70% and 90% of the calves vaccinated intranasally and intramuscularly, respectively, maintained SN antibody for 6 months after vaccination. In a field trial, a natural BRS virus infection occurred about 5 months after the start of the trial. Ten of the 16 unvaccinated control calves showed respiratory symptoms due to BRS virus infection. On the contrary, all of the 68 vaccinated calves exhibited no symptoms at all, indicating efficacy of the vaccine.  相似文献   

17.
OBJECTIVE: To determine whether passively acquired antibodies prevent development of a protective immune response to live virus in calves. ANIMALS: 18 calves. PROCEDURES: Calves were caught immediately after birth and tested free of bovine viral diarrhea virus (BVDV) and serum antibodies against BVDV. Within 48 hours, 12 calves were fed colostrum that contained antibodies against BVDV and 6 calves received BVDV antibody free milk replacer. Three milk replacer fed and 6 colostrum fed calves were exposed to virulent BVDV2-1373 at 2 to 5 weeks of life when passively acquired serum antibody titers were high. After serum antibody titers against BVDV had decayed to undetectable concentrations (at 7 to 9 months of age), the 3 remaining milk replacer fed calves, 6 colostrum fed calves previously exposed to BVDV2-1373, and 6 colostrum fed calves that had not been exposed to the virus were inoculated with BVDV2-1373. RESULTS: Passively acquired antibodies prevented clinical disease in inoculated colostrum fed calves at 2 to 5 weeks of life. Serum antibody titers did not increase in these calves following virus inoculation, and serum antibody titers decayed at the same rate as in noninoculated colostrum fed calves. Inoculated colostrum fed calves were still protected from clinical disease after serum antibody titers had decayed to nondetectable concentrations. Same age colostrum fed calves that had not been previously exposed to the virus were not protected. CONCLUSIONS AND CLINICAL RELEVANCE: A protective immune response was mounted in calves with passive immunity, but was not reflected by serum antibodies titers. This finding has implications for evaluating vaccine efficacy and immune status.  相似文献   

18.
OBJECTIVE: To determine the effect of maternally derived antibodies on induction of protective immune responses against bovine viral diarrhea virus (BVDV) type II in young calves vaccinated with a modified-live bovine viral diarrhea virus (BVDV) type I vaccine. DESIGN: Blinded controlled challenge study. ANIMALS: 24 neonatal Holstein and Holstein-cross calves that were deprived of maternal colostrum and fed pooled colostrum that contained a high concentration of (n = 6) or no (18) antibodies to BVDV. PROCEDURE: At 10 to 14 days of age, 6 seropositive and 6 seronegative calves were given a combination vaccine containing modified-live BVDV type I. All calves were kept in isolation for 4.5 months. Six calves of the remaining 12 untreated calves were vaccinated with the same combination vaccine at approximately 4 months of age. Three weeks later, all calves were challenged intranasally with a virulent BVDV type II. RESULTS: Seronegative unvaccinated calves and seropositive calves that were vaccinated at 2 weeks of age developed severe disease, and 4 calves in each of these groups required euthanasia. Seronegative calves that were vaccinated at 2 weeks or 4 months of age developed only mild or no clinical signs of disease. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicate that a single dose of a modified-live BVDV type-I vaccine given at 10 to 14 days of age can protect susceptible young calves from virulent BVDV type II infection for at least 4 months, but high concentrations of BVDV-specific maternally derived antibodies can block the induction of the response.  相似文献   

19.
牛病毒性腹泻病毒感染对猪瘟免疫的影响   总被引：2，自引：0，他引：2  
张慧英 《四川畜牧兽医》2010,37(10):21-22,25
猪瘟病毒（CSFV）与同属的牛病毒性腹泻病病毒（BVDV）同源性较高,抗原性上有交叉。本次调查对368份猪瘟免疫猪血清样本进行BVDV抗原检测,其中7份呈阳性,阳性率1.90%。对7份BVDV阳性血清采用ELISA和IHA两种方法检测猪瘟（CSFV）抗体水平,抗体合格率偏低,两者的结果符合率为71%。研究表明：BVDV在一定程度上干扰了猪瘟疫苗的免疫效果,影响抗体水平。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号